CRISPR/Cas13-mediated Dynamin 2 reduction therapy in a canine model of <i>DNM2</i> -related centronuclear myopathyAndrea Carlier, Isabel Punzón|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 0